OSE Immunotherapeutics Receives €5.2 M in Public Funding for the Clinical Development of CoVepiT, its Second Generation COVID-19 Vaccine
CoVepiT demonstrated generation of sentinel memory T cells with long-term protective effect against COVID-19 in preclinical and human ex vivo...










